Physician profile
Ivan A Baumwell
NPI 1891709382
$9,475.84
in general payments reported to CMS, 2019-2025
27 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $961 · 2021: $633 · 2022: $1,446 · 2023: $1,251 · 2024: $1,450 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,724.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,723.57 | 2019-2025 | Centurion, Rocklatan, Ngenuity |
| Allergan, INC. | $1,637.19 | 2019-2022 | |
| Abbvie INC. | $1,520.49 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $803.27 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| New World Medical,INC. | $704.17 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $644.28 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $377.54 | 2022-2025 | Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $344.83 | 2019-2021 | |
| Oyster Point Pharma, INC. | $276.50 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $234.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $210.53 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $188.93 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $164.95 | 2024-2025 | Omni Surgical System |
| Glaukos Corporation | $131.53 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Carl Zeiss Meditec, INC. | $75.52 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $69.62 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $68.27 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $46.75 | 2020 | |
| Apellis Pharmaceuticals, INC. | $39.86 | 2023-2025 | Syfovre |
| Horizon Therapeutics Plc | $37.12 | 2021-2023 | Tepezza |
| Astellas Pharma US INC | $32.86 | 2024 | Izervay |
| Harrow Eye, LLC | $31.62 | 2025 | Iheezo |
| Ivantis, INC | $25.96 | 2020 | |
| Boston Scientific Corporation | $23.43 | 2021 | |
| Travere Therapeutics, INC. | $22.91 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.18 | 2024 | Acthar |
| Kala Pharmaceuticals, INC. | $19.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Baumwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.